- Home
- LBRX vs REX Comparison
LBRX vs REX Comparison
Compare LBRX & REX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBRX | REX |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2025 | 1994 |
Fundamental Metrics
Financial Performance| Metric | LBRX | REX |
|---|---|---|
| Price | $39.73 | $40.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $58.00 | N/A |
| AVG Volume (30 Days) | ★ 432.2K | 216.3K |
| Earning Date | 11-05-2026 | 12-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.22 | N/A |
| EPS | N/A | ★ 1.62 |
| Revenue | N/A | ★ $650,487,000.00 |
| Revenue This Year | N/A | $18.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $25.68 |
| Revenue Growth | N/A | ★ 1.24 |
| 52 Week Low | $14.32 | $30.46 |
| 52 Week High | $50.16 | $53.36 |
Technical Indicators
Market Signals| Indicator | LBRX | REX |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 39.36 |
| Support Level | $22.85 | $39.04 |
| Resistance Level | $49.74 | $44.82 |
| Average True Range (ATR) | 2.21 | 1.48 |
| MACD | 0.49 | -0.26 |
| Stochastic Oscillator | 93.52 | 0.21 |
Price Performance
Historical ComparisonAbout LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.